US pharmaceutical company Bristol-Myers Squibb Co. reported first quarter financial results on Friday, beating analyst expectations.

The company reported revenue of $11.648 billion (up 5% year-over-year) vs. $11.349 billion expected.

Earnings per share reported at $1.96 per share (a 13% increase year-over-year) vs. $1.91 per share estimate.

”We continue to execute against our strategic priorities, deliver solid revenue and earnings growth and advance our product pipeline,” company CEO, Giovanni Caforio said on the results.

”Thanks to our team’s hard work and dedication, we achieved regulatory approvals of Opdualag and Camzyos, our new first-in-class medicines for patients living with metastatic melanoma and symptomatic obstructive hypertrophic cardiomyopathy, respectively. These milestone achievements, combined with our promising product pipeline and strong financial flexibility, provide a solid foundation that will enable us to deliver sustained growth and long-term benefits for our patients,” Caforio concluded.

Bristol-Myers Squibb Co. chart

The stock was down by 2.5% on Friday at $75.21 per share.

Here is how the stock has performed in the past year:

• 1 Month +1.96%
• 3 Month +96%
• Year-to-date +72%
• 1 Year +59%

Bristol-Myers Squibb price targets

• Morgan Stanley: $64
• Wells Fargo: $65
• Goldman Sachs: $72
• Barclays: $66

Bristol-Myers Squibb Co. is the 65^th largest company in the world with a market cap of $160 billion.

You can trade Bristol-Myers Squibb Co. (BMY) and many other stocks from the NYSE, NASDAQ, HKEX and the ASX with GO Markets as a Share CFD.

Sources: Bristol-Myers Squibb Co., TradingView, CompaniesMarketCap